Pınar Çoban eşdur

Pınar Çoban eşdur

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Lung Cancer Management
Verified
Journal Article
Open access
MBMehmet Emin Buyukbayram
Mehmet Emin Buyukbayram
ZHZekeriya Hannarici
Zekeriya Hannarici
AYAli Yilmaz
Ali Yilmaz
ATAykut Turhan
Aykut Turhan
AÇAlperen Akansel Çağlar
Alperen Akansel Çağlar
STSalim Basol Tekin
Salim Basol Tekin
Aim: The tumor microenvironment of NSCLC with driver mutations, such as EGFR, ALK and ROS, is less inflammatory. Materials & methods: This retrospective study included 38 patients with NSCLC driver... Plain language summary Lung cancer is the most common cancer worldwide and has a high mortality rate. Overall survival expectancy in metastatic NSCLC has increased from 11 months to 18 months. The ... Tweetable abstract Peripheral inflammatory parameters may be associated with survival in driver mutation NSCLC, in contrast to a less inflammatory tumor microenvironment.

5 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
ZHZekeriya Hannarici
Zekeriya Hannarici
ATAykut Turhan
Aykut Turhan
MBMehmet Emin Buyukbayram
Mehmet Emin Buyukbayram
AÇAlperen Akansel Çağlar
Alperen Akansel Çağlar
MBMehmet Bilici
Mehmet Bilici
EBElif Bayraktar
Elif Bayraktar
Background: Finding dependable prognostic biomarkers for metastatic colorectal cancer (mCRC) is crucial. The albumin-to-carcinoembryonic antigen (CEA) ratio (ACR), a measure of nutritional-inflammatory status and tumor load, has emerged as a promising prognostic indicator. This study assessed ACR’s prognostic value of ACR in patients with mCRC. Methods: This retrospective study included 125 patients with mCRC followed at our institution between July 2010 and March 2022. ROC curve analysis was used to determine the optimal cutoff values for ACR, prognostic nutritional index (PNI), lymphocyte-to-monocyte ratio (LMR), and CEA. Kaplan–Meier and Cox regression analyses were used to evaluate progression-free survival (PFS) and overall survival (OS). Results: PFS and OS were 13.3 and 26.0 months, respectively. Patients with an ACR ≥ 4.24 experienced significantly longer PFS (16.8 vs. 11.0 months; p = 0.001) and OS (32.0 vs. 22.3 months; p < 0.001) compared with those with ACR < 4.24. In univariable analyses, ACR was significantly associated with both PFS and OS, whereas PNI, LMR, and CEA were associated with OS only. In multivariable Cox regression models ACR showed a significant association with both PFS (HR 0.413; 95% CI: 0.265–0.643; p < 0.001) and OS (HR 0.341; 95% CI: 0.210–0.551; p < 0.001), while maintenance therapy was significantly associated with PFS only and ECOG performance status, LMR and PNI with OS only. Conclusions: ACR appears to be a cost-effective biomarker that is associated with PFS and OS in mCRC. These findings suggest that ACR may have potential value for prognostic assessment and risk stratification in patients with mCRC.

7 August 2025
Verified
Book Chapter
Closed access
PEPınar Çoban eşdur
Pınar Çoban eşdur
Küçük hücreli dışı akciğer kanseri (KHDAK) kansere bağlı ölümün en önemli sebeplerinden birisi olup etiyolojide sigara dışında; arsenik, asbest, berilyum, kadmiyum, krom, kömür dumanı, dizel dumanı, nikel, silika, is ve uranyum gibi etkenlerde yer almaktadır (10-12). KHDAK’ ler nonskuamöz (çoğu adenokarsinom olmakla beraber, büyük hücreli karsinom ve diğer tipler) ve skuamöz (epidermoid) olmak üzere iki ana gruba ayrılmaktadır (16). Bazı prognostik faktörler KHDAK’de sağ kalımı belirler. İyi prognostik faktörler arasında; tanı anında erken evre olması, iyi performans durumu (ECOG 0-1), kadın cinsiyet ve kilo kaybının %5’den az olması yer almaktadır (17). FDA tarafından karşılanan hedefe yönelik tedavilerin verilebilmesi için; metastatik adenokarsinom, büyük hücreli karsinom ve NOS olarak bilinen alt tip adlandırılamayan hastalara moleküler testlerin yapılması önerilmektedir. Metastatik skuamöz hücreli karsinomlu hastalarda da bu testler düşünülebilir (18-19). Adenokarsinom alt tipi için yapılan 5 yıllık survi analizinde; lokal hastalıkta %70.1, bölgesel lenf nodu tutulumu olanlarda %44.7, uzak oran metastazı olanlarda ise %9.6 olarak saptanmıştır (22). Tedavi seçenekleri arasında; cerrahi, radyoterapi ve sistemik tedavi yer almaktadır. Evre I ve II de cerrahi, evre IIIA da neoadjuvan (ameliyat öncesi) tedavi sonrası operasyon için tekrar değerlendirilmesi, evre IIIB-C de kemoradyoterapi ve evre IV hastalıkta ise sistemik tedavi uygulanması önerilmektedir (25). Metastatik KHDAK de platin bazlı kombinasyon tedavisinin, hedefe yönelik tedavi veya immünoterapiye uygun olmayan ileri evre ve küratif tedavisi mümkün olmayan hastalar için en iyi destek tedaviden daha üstün olduğunu göstermektedir (27). Klavuzlar ileri evre ve metastatik hastalık için birinci basamak sistemik tedavi alan hastaların BT taraması ile tümör yanıtı açısından değerlendirilmesini önermektedir. Yanıt değerlendirmesi için ilk tedavinin 2.siklusu sonrası ve daha sonra bilinen veya yüksek riskli hastalık bölgelerinin BT'si (kontrastlı veya kontrastsız) çekilerek yada klinik olarak şüphelenildiğinde her 2 ila 4 siklusta bir görüntüleme yapılmalıdır (29). Non-small cell lung cancer (NSCLC) is one of the most important causes of cancer-related deaths and in addition to smoking, factors such as arsenic, asbestos, beryllium, cadmium, chromium, coal smoke, diesel smoke, nickel, silica, soot and uranium are also involved in the etiology (10-12). NSCLCs are divided into two main groups as nonsquamous (mostly adenocarcinoma, but also large cell carcinoma and other types) and squamous (epidermoid) (16). Some prognostic factors determine survival in NSCLC. Good prognostic factors include early stage at diagnosis, good performance status (ECOG 0-1), female gender and weight loss of less than 5% (17). In order to provide targeted therapies approved by the FDA, molecular testing is recommended for patients with metastatic adenocarcinoma, large cell carcinoma and NOS, the subtype of which cannot be named. These tests may also be considered in patients with metastatic squamous cell carcinoma (18-19). In a 5-year survival analysis for the adenocarcinoma subtype, it was found to be 70.1% in local disease, 44.7% in those with regional lymph node involvement, and 9.6% in those with distant metastasis (22). Treatment options include surgery, radiotherapy, and systemic therapy. Surgery is recommended for stage I and II, neoadjuvant (preoperative) treatment followed by reevaluation for surgery in stage IIIA, chemoradiotherapy in stage IIIB-C, and systemic therapy in stage IV disease (25). In metastatic NSCLC, platinum-based combination therapy is shown to be superior to best supportive care for advanced-stage patients who are not eligible for targeted therapy or immunotherapy and who cannot be curatively treated (27). Guidelines recommend that patients receiving first-line systemic therapy for advanced-stage and metastatic disease should be evaluated for tumor response with CT scan. Imaging should be performed after the second cycle of initial treatment for response assessment and then every 2 to 4 cycles with CT (with or without contrast) of known or high-risk disease sites or when clinically suspected (29).

15 January 2025 in Medical Records
Verified
Journal Article
Open access
PDF file
AÇAlperen Akansel Çağlar
Alperen Akansel Çağlar
ATAykut Turhan
Aykut Turhan
PEPınar Çoban eşdur
Pınar Çoban eşdur
YSYasin Emrah Soylu
Yasin Emrah Soylu
MBMehmet Bilici
Mehmet Bilici
STSalim Başol Tekin
Salim Başol Tekin
Aim: Cancer is a major cause of death. Globocan data shows 20 million new cancer cases and 9.7 million cancer deaths a year. Lung cancer is the most common cancer globally, followed by breast, colorectal, prostate and stomach cancers. Cancer types vary by age, gender, race, and region. Documenting regional cancer data is crucial for screening, early diagnosis, and treatment of common cancers, as well as understanding the underlying causes. Despite the high incidence of upper gastrointestinal (GI) cancers in eastern Türkiye, there is little documented evidence on specific cancer types in these regions. Material and Method: In order to investigate the incidence of cancer in our region, the medical records of 6,603 patients diagnosed with cancer and subsequently treated in our clinic between 2018 and 2023 were analysed and specific cancer sites were recorded. Results: It has been demonstrated that cancers of the upper GI tract, represent the most prevalent cancer site, accounting for 21.2% (n=1403) of all cases. This equates to one in every five patients diagnosed with cancer. Additionally, significant findings were yielded with respect to other forms of cancer. Conclusion: It is imperative to document these data to highlight the necessity for investigating and preventing the underlying causes of upper GI cancer in our region. Furthermore, the establishment of screening programs for early diagnosis and intensified research on treatment modalities are crucial steps in combating this disease.

7 August 2025
Verified
Book
Open access
PDF file
ŞSŞermin Dinç Sonuşen
Şermin Dinç Sonuşen
IBİbRahim Bilen
İbRahim Bilen
ÖKömer Faruk Kuzu
ömer Faruk Kuzu
ÖDÖzden Demir
Özden Demir
HBHülya Odabaşı bükün
Hülya Odabaşı bükün
MKMerve Köse
Merve Köse

25 December 2025 in Düzce Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
MBMehmet Emin Buyukbayram
Mehmet Emin Buyukbayram
ZHZekeriya Hannarici
Zekeriya Hannarici
ATAykut Turhan
Aykut Turhan
SGSalih Gölcüklü
Salih Gölcüklü
PEPınar Çoban eşdur
Pınar Çoban eşdur
STSalim Başol Tekin
Salim Başol Tekin
Aim: Locally advanced rectal cancer (LARC) is associated with high mortality. Although neoadjuvant chemoradiotherapy (nCRT) is the mainstay of treatment, the expected pathological response is inadequate. Research on total neoadjuvant treatment (TNT) is ongoing. This study aimed to investigate the significance of certain inflammatory and metabolic parameters in predicting treatment response and survival. Material and Methods: Data from 57 patients with LARC who underwent nCRT or TNT between 2010 and 2023 were retrospectively analyzed. The systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) were calculated from the results of the blood samples collected before the initiation of treatment, along with the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and erythrocyte distribution width (RDW)-to-lymphocyte ratio (RLR). Results: Of the patients, 52 (91.2%) had adenocarcinoma, while 5 (8.8%) had mucinous or signet-ring histology. Among 55 patients with available data, 42 (76.4%) were clinically N+. Seven (12.3%) received TNT. According to the Dworak regression score, 48 (84.2%) had a poor, and 9 (15.8%) had a good response. Six (10.5%) patients had a pathological complete response. An increase in SII per 100 units (HR=1.081, 95% CI: 1.005-1.162, p=0.036) and in RLR (HR=1.197, 95% CI: 1.025-1.398, p=0.023) was significantly associated with disease-free survival (DFS) in univariate analysis, but not in the multiple model. Conclusion: There was no significant association between the Dworak regression score and the inflammatory and metabolic parameters in response to nCRT in LARC. Further studies are needed to determine the relationship between the RLR, a novel parameter, and DFS.